Physician profile
Marcus H Loo
NPI 1053315614
$2,969.06
in general payments reported to CMS, 2019-2025
24 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $333 · 2021: $810 · 2022: $617 · 2023: $517 · 2024: $176 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.36 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,140.86 | 2019-2024 | Myrbetriq, Xtandi |
| Merck Sharp & Dohme LLC | $383.76 | 2020-2024 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $342.43 | 2019-2024 | |
| Pfizer INC. | $192.16 | 2019-2025 | |
| Janssen Biotech, INC. | $161.58 | 2019-2025 | Erleada |
| Ethicon US, LLC | $135.66 | 2023 | Echelon Flex, Stratafix, Surgicel Nu-Knit |
| Myovant Sciences INC. | $89.11 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $65.21 | 2023-2025 | Gemtesa, Orgovyx |
| Tolmar Pharmaceuticals, INC. | $60.82 | 2021-2022 | |
| Coloplast Corp | $44.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.70 | 2021 | |
| Myriad Genetic Laboratories, INC. | $35.44 | 2022-2023 | Prolaris |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Progenics Pharmaceuticals, INC. | $26.67 | 2025 | |
| Urovant Sciences INC | $25.93 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hollister Incorporated | $24.66 | 2022 | |
| Amgen INC. | $22.78 | 2023 | Xgeva |
| Tolmar, INC. | $22.78 | 2023 | |
| Blue Earth Diagnostics | $22.54 | 2022 | |
| Endo Pharmaceuticals INC. | $21.58 | 2021 | |
| Verity Pharmaceuticals INC. | $20.00 | 2023 | Trelstar |
| Dentsply Ih INC. | $19.60 | 2021 | |
| Allergan, INC. | $18.18 | 2019 | |
| Accord Healthcare, INC. | $17.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Loo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.